Inogen Inc. reported third quarter 2025 revenue of $92.4 million, a 4.0% increase year-over-year. The company posted a GAAP net loss of $5.3 million and an adjusted net loss of $0.5 million, compared to a GAAP net loss of $6.0 million and an adjusted net loss of $2.6 million in the prior year period. Adjusted EBITDA was $2.3 million, marking the third consecutive quarter of positive adjusted EBITDA. Operating cash flow was $2.2 million, with cash, cash equivalents, marketable securities, and restricted cash totaling $124.5 million at quarter-end and no debt outstanding. Inogen reiterated its full year 2025 revenue outlook of $354 million to $357 million and raised adjusted EBITDA guidance to approximately $2.0 million. The company also initiated a limited market release of the Simeox airway clearance device in the United States during the quarter.